Anti-PDL1 antibody formulations
US10875922B2 · kind B2 · utility
0Cited by
19References
31Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Mar 25, 2016 |
| Grant date | Dec 29, 2020 |
| Priority date | — |
| Expiry date | Dec 14, 2036 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/76
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention provides stable aqueous pharmaceutical formulations comprising an anti-PDL1 antibody. The invention also provides methods for making such formulations and methods of using such formulations.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.